

2000 2001

480

1

, ,

1997 4 6 MMR 2

7 MMR 가 2

2 97.1%

4 6 MMR

2 2005

1990 , 1993 1994

, 2000 10

, 2000 12 3

가

2005

95%

1,000 2,000

, 1990 1994

2 , 2000 10

, 2000 12

2001 5 5

95% 8 16 4 가 2

MR 1

. MR 2001 5 21 (2 3%), 가

2001 7 13 (10 15%)

10

5,849,816 MR 2 3 ,

4,846,485 (82.9%) , 4 7

2

832,495 (14.2%)

5,849,816 5,678,980 (97.1%) 95%

MR , 가

1,207

2 40%가
282 . . 23,000
,
,
,
(Enzyme linked immunosorbent assay, ELISA) Enzygnost Anti-Measles Virus IgG
CDC WHO
, 5
, 2005
가
1.
1997 MMR 2 4 6
MMR 2 10
가
(Susceptible level for measles)
「
」
16 .
282 . . (7 18)
23,000
,
16 . 7 18
16 .
,
1




Fig. 1.

94 . .
282 . . 23,000
,
,
,
,
(Enzyme linked immunosorbent assay, ELISA) Enzygnost Anti-Measles Virus IgG
2000 12
89.4%,
6%
(Campaign)
84.2%
,
95%
1 (7) 3 (15)
(Fig. 2).
2.
2001
4 6 2 MMR
95%
MMR
2001 1 2001 3
72 6




Fig. 2.

282 : 8 2 2001

MMR , '2 16 . 244 (2 , '2 MMR , 1 , () 2 3 , 2 3 . , 2 , , MMR . . 11,940 () 6 () . 2001 5 2001 7 2001 689,436 , 2 686,194 99.5% , 10,706 5,803 , 2,840 , 2 1,910 , 243 . 682,343 99.4% . 4 30 95% 6 12 7 95% MR . 3 . CDC WHO , WHO/ 1) UNICEF MR (Serum Institute of India LTD.) 684 2001 5 21 2001 7 14 8 16 12 3 (1) 2 . 2) 2 8 () MR . MR 4 6 MMR , MMR () 2 10 2 . 1 가 84 2 . , , 13 ' 가 , (1) , . (16) , . (244) . , , , 3) 2001 5 21 2001 9 28 10

5,849,816
4,846,485 (82.9%)
‘2
832,495 (14.2%)
5,849,816 5,678,980 (97.1%)
15
95%
17,955 0.3% , 151,632
2.6%
4)
3가
가
12
1339
99
4 , 1
1,136
480
1
1

1,541
가
가
2001 7 210 , 8 32 , 9
9 , 10 1
8
42 , 36 6
10 16 3 , 18 22 3




Fig. 3.

3 가 4
80.9%가
3
23.6 (1,136 / 4,804,277)
10
12 1339
5,093




Fig. 4.




Fig. 5.

. 10 16 2

2

4 6 2 MMR

95%

EDI

가

가 , 16

1) 95%

2) 6 2

580 97.1% 1

3)

가

가

가

가